AETHERA is the first study to show a significant effect of a post-transplant strategy in patients at high risk of relapse after transplant.
—Brad S. Kahl, MD
AETHERA is the first study to show a significant effect of a post-transplant strategy in patients at high risk of relapse after transplant,” said Brad S. Kahl, MD, Associate Professor at the University of Wisconsin School of Medicine and Public Health, Madison.
“The question remains whether brentuximab is delaying inevitable relapse or taking patients who are destined to relapse to a cure. We don’t have the answer to that question. It will take longer follow-up,” Dr. Kahl said. ■
Disclosure: Dr. Kahl has received consulting fees from Seattle Genetics.
In patients with Hodgkin lymphoma who are at risk for disease progression following autologous stem cell transplantation, early consolidation with brentuximab vedotin (Adcetris) post-transplant significantly improved progression-free survival compared with placebo in the phase III AETHERA trial.1...